In 2018, HiFiBiO received $37.5 million in Series B funding from sources including Sequoia Capital and LYFE Capital.

In July of the same year, HiFiBiO entered into a strategic partnership with Japanese pharma major Takeda to focus on discovering therapies in Takeda's key therapy areas.